Mammoth emerges, among first diagnostic-focused CRISPR companies

Mammoth Biosciences (San Francisco, Calif.) debuted on Thursday with a CRISPR-based diagnostic platform and an exclusive license to IP covering work from CRISPR pioneer Jennifer Doudna. While CRISPR-based therapeutics have garnered the most attention from biotech and pharma communities, Mammoth emerges as one of the first companies to exclusively focus on diagnostics applications (see BioCentury Innovations, April 26).

Doudna is a professor of chemistry and of biochemistry and molecular biology at the University of California Berkeley. She is also co-founder of Mammoth and CRISPR therapeutics companies Editas Medicine Inc. (NASDAQ:EDIT) and Intellia Therapeutics Inc. (NASDAQ:NTLA)...